ABSTRACTS

P3.14 Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models

M. Binsfeld, M. Hannon, S. Humblet-Baron, Y. Beguin, F. Baron, J. Caers

P2.09 Refractory anemia with ringed sideroblasts upon linezolid treatment

K. Vanhouteghem, B. Cauwelier, P. Costers, D. Selleslag, J. Emmerechts

P2.10 Acquired von Willebrand disease in CML : a case report

C. Amicone, L. Plawny

P3.01 Hematopoietic progenitor cell count in mobilized peripheral blood by Sysmex XE-2100: added value in clinical practice?

S. Desmet, T. Maenhout, E. Moreau, I. Van Haute, D. Deeren

P3.02 Autologous Hematopoietic Stem Cell Transplantation in Crohn’s Disease: Results from our first 14 patients

D. Dierickx, A. Van Besien, S. Vermeire, G. Verhoef, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans

P3.03 Study of immune recovery in a randomized phase II trial of sequential double autologous transplantation with unmanipulated or AC133+ PBSC in patients with multiple myeloma

M. Hannon, S. Servais, R. Schots, E. Castermans, L. Seidel, A. Gothot, E. Baudoux, O. Giet, N. Wanten, E. Willems, C. Daulne, I. Van Riet, Y. Beguin, F. Baron

P3.04 Effects of tocilizumab® on Th17 cells differentiation in a humanized mouse model of xenogenic graft-versus-host disease

L. Delens, S. Servais, M. Hannon, G. Ehx, G. Fransolet, S. Dubois, Y. Beguin

P3.05 Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation

A. Jaspers, F. Baron, J. Maertens, B. De Prijck, R. Schots, C. Bonnet, K. Hafraoui, E. Willems, S. Servais, G. Fillet, Y. Beguin

P3.06 Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning

M. Hannon, Y. Beguin, G. Ehx, S. Servais, L. Seidel, C. Graux, J. Maertens, T. Kerre, C. Daulne, M. De Bock, M. Fillet, A. Ory, E. Willems, A. Gothot, S. Humblet-Baron, F. Baron

P3.07 Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: a rare infectious complication

P. Vlummens, D. van de Putte, L. Libbrecht, L. Noens, V. Van Hende, T. Kerre

P3.08 Multifocal periostitis as a long-term complication of voriconazole use in an allogeneic stem cell transplant recipient

P. Vlummens, P. Gykiere, B. Lambert, E. Steel, T. Kerre

P3.09 Occurrence of mild spontaneous graft-versus-host-disease after autologous stem cell transplantation for multiple myeloma

I. Moors

P3.10 Kaposi’s Sarcoma: a rare complication reflecting immune suppression after autologous stem cell transplantation

B. Heyrman, A. De Becker, K. Fostier, F. Trullemans, R. Schots

P3.11 Remitting seronegative symmetrical synovitis with pitting edema after allogeneic stem cell transplantation

A. Devresse, S. Daens, R. Lhommel, L. Knoops, D. Bauwens, E. Van den Neste, X. Poiré

P3.12 Devised performance as a tool for public engagement in acute haematological cancers

A. Mermikides, M. Mermikides, A. Tanczos, R. Seymour, A. Kirkham, C. Lofthouse, A. Nasrat, E. Weitkamp, A. Van De Velde

P3.13 Plerixafor in autologous haematopoietic stem cell mobilization in Belgium

D. Selleslag, C. Lambert, P. Zachée, D. Dierickx

P2.08 Short delay of occurrence of myelodysplasia after Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NETs)

G. Claes, J. Nguyen, N. Charette, G. Machiels, M. Vercruyssen, S. Wittnebel, N. Meuleman, D. Bron

P3.15 Clofarabine as salvage therapy and bridge to transplantation in acute leukemia. A single center experience

G. Di Prinzio, C. Cornil, E. Collinge, A. Devresse, P.D.M. Katoto, V. Havelange, E. Van den Neste, X. Poiré, M.C. Vekemans

P3.17 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease

G. Fransolet, G. Ehx, J. Somja, L. Belle, P-V. Drion, S. Humblet-Baron, Y. Beguin, B. Baron

P3.19 Spurious Decrease In The Wbc Count Measured By The Wnr Channel Of Xn Haematology Analyzer (Sysmex) Could Be Associated With Metastatic Adenocarcinoma

V.T.P. Nguyen, D. Gobin, R. Li, B. Cantinieaux

P4.01 Retrospective study of the significance of positive DAT

H. Claerhout, K. Ver Elst, S. Weekx, S. Vermeiren

P4.02 Hepcon® HMS and Hemochron® allow for similar anticoagulation management during cardiopulmonary bypass in low-risk patients undergoing cardiac surgery

C. Lecut, C. Clotuche, M.G. Lagny, P. Péters, J.O. Defraigne, A. Gothof, R. Larbuisson

P4.03 Introduction of Type and Screen testing in patients from the hematology and oncology department: comparison with blood cross-matching

M. Hofmans, P. Meeus, E. Bailleul

P4.04 Point-of-care devices assessing platelet function and clotting in sepsis: effect of thrombocytopenia and analytical variables

A. Gothot, C. Gosset, C. Lecut, P. Péters, P. Massion

P4.05 Anemia in a geriatric hospitalized population: an old disorder

L. Sattar, P. Hermans, T. Pepersack

P4.06 A pernicious anemia hiding under the guise of a normocytic anemia

A. Dermine, J. Dewulf, J-P. Defour, M.C. Vekemans

P4.07 Diagnosis of congenital von Willebrand disease during a pre-operative screening in a multiple myeloma patient

M. EI Ouaaliti, L Rong, P. Nguyen, D. Gobin, D. Bron, B. Cantinieaux

P4.08 Two cases of immune-mediated early-onset neonatal thrombocytopenia: a case presentation

K. Vanhouteghem, H. Vanhouteghem, K. De Schynkel, K. Van Haver, A. Luyckx

P4.09 Evaluation of Schistocyte Analysis by a Novel Automated Digital Cell Morphology Application

AS. Hervent, M. Godefroid, B. Cauwellier, J. Billiet, J. Emmerechts

P4.10 De novo thrombotic microangiopathy after non-renal solid organ transplantation

D. Dierickx, A. Verbiest, J. Pirenne, G. Verhoef, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans

P4.11 Influence of platelet clumps on platelet function analyzer (PFA)-200® testing

S. Mulliez, G. Hallaert, D. van Roost, A. Vantilborgh, K. Devreese

P4.12 Comparison Between Polyspecific Reagent And Anti-Igg For The Detection Of Irregular Antibodies By Indirect Antiglobulin Test With Biovue-Ortho®

N. Tasiaux, J. Honoré, A. Dascotte, C. Potvliege

P1.12 Tumor lysis syndrome: monocentric evaluation of a predictive tool

D. Dierickx, K. Saevels, G. Verhoef, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans

O.1 Results from the Belgian mantle cell lymphoma registry

V. Vergote, A. Janssens, A. Van Hoof, All Other Members of The BHS

O.2 Analysis of Phenotype and Outcome in Essential Thrombocythemia with CALR and JAK2 mutations

C. AL Assaf, F. Van Obbergh, J. Billiet, E. Lierman, T. Devos, C. Graux, A.S. Hervent, T. Tousseyn, P. De Paepe, P. Papadopoulos, L. Michaux, P. Vandenberghe

O.3 The anti-angiogenic peptide Anginex blocks osteoclastogenesis

J. Muller, M. Binsfeld, S. Dubois, G. Carmeliet, Y. Beguin, R. Heusschen, J. Caers

O.4 Impact of pre-transplant infusion of antithymocyte globulin (ATG-Fresenius) on immune recovery after high intensity conditioning allogeneic stem cell transplantation

S. Servais, C. Menten, Y. Beguin, C. Daulne, L. Delens, E. Willems, M. Hannon, F. Baron

O.5 Azacytidine augments regulatory T cells and prevents experimental xenogeneic graft-versus-host disease

G. Ehx, G. Fransolet, L. De Leval, S. Lucas, S. d’Hondt, M. Hannon, P-V. Drion, Y. Beguin, S. Humblet-Baron, B. Baron

O.6 Non-invasive Detection of Genomic Imbalances in Hodgkin/Reed-Sternberg Cells in Early and Advanced Stage Hodgkin Lymphoma by Sequencing of Circulating Cell-free DNA

P. Vandenberghe, I. Wlodarska, T. Tousseyn, L. Dehaspe, D. Dierickx, M. Verheecke, A. Uyttebroeck, O. Bechter, M. Delforge, V. Vandecaveye, N. Brison, G.E.G. Verhoef, E. Legius, F. Amant, J.R. Vermeesch

P1.01 Myeloid Derived Suppressor Cells induce Multiple Myeloma cell survival through AMPK activation

K. De Veirman, J. van Ginderachter, N. De Beule, S. Lub, A. Maes, E. De Bruyne, E. Menu, I. Van Riet, K. Vanderkerken, E. Van Valckenborgh

P1.02 In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

K. Maes, E. De Smedt, A. Kassambara, D. Hose, A. Seckinger, E. Van Valckenborgh, E. Menu, B. Klein, K. Vanderkerken, J. Moreaux, E. De Bruyne

P1.03 Thymoquinone induces DNA damage, apoptosis and inhibits proliferation in germinal center subtype of diffuse large B-cell lymphoma

M. Berehab, R. Rouas, D. Douaa, D. Bron, P. Lewalle, P. Martiat, M. Merimi

P1.06 Bilateral Bell’s palsy leading to the diagnosis of chronic lymphocytic leukemia

C. Cornil, E. Collinge, G. Di Prinzio, A. Devresse, J-P. Defour, P. Saussoy, L. Michaux, L. Knoops, M.C. Vekemans, A. Ferrant

P1.07 Unusual progression of a B-cell non-Hodgkin’s lymphoma

E. Collinge, A. vanden Daelen, L. Marot, A. Camboni, J-P. Defour, P. Saussoy, L. Michaux, M.C. Vekemans, L. Knoops

P1.08 Multiparameter flow cytometric analysis of composite lymphoma: case report of a mantle cell lymphoma associated with a B-cell chronic lymphocytic leukemia and an aberrant T cell subset

J. Foguenne, M. Simul, R. Keutgens, F. Tassin, C. Bonnet, Y. Beguin, M. Jamar, F. Lambert, A. Gothot

P1.09 Follicular dendritic cell sarcoma in the retropharyngeal region: diagnostic and therapeutic challenges

H.R. Kourie, J. Nguyen, X. Wang, T. Gil, R. Dewind, P. Lewalle, N. Meuleman, D. Bron

P1.10 Lactic acidosis as an atypical presentation of a diffuse large B-cell lymphoma

V. Galle, C. De Vriendt, P. Vlummens, A. Vantilborgh, D. Benoit, E. De Coster

P1.11 Primary Cutaneous T-cell Lymphoproliferative Disorders Expressing a CD8 and CD30-Positive Phenotype

M. Shwe, L. Marot, L. Sacre, A. Camboni, S. Olivier

P1.13 Temsirolimus in daily clinical practice: results from the Belgian mantle cell lymphoma registry

A. Janssens, V. Vergote, A. Van Hoof, All Other Members of The BHS

P1.14 Monoclonal B-cell lymphocytosis (MBL): results of a routine screening in a general hospital

G. Claes, D. Bron, M. Maerevoet, S. Benghiat, V. De Wilde, B. Bailly, N. Istaces, J. Brauner, O. Pradier, N. Meuleman

P1.15 Outcome after salvage chemotherapy with DHAP/ICE-type regimens and attempt to transplant in patients with aggressive lymphoma: experience of a single centre

P.D.M. Katoto, N. Vanlangendonck, V. Havelange, X. Poiré, C. Lambert, M.C. Vekemans, A. Ferrant, V. Lannoy, E. Van den Neste

P1.16 Monoclonal B-cell lymphocytosis (MBL): results olmpact of extracellular vesicles from mesenchymal stromal cells-based microenvironment on Chronic Lymphocytic Leukemia B-cells

E. Crompot, M. Van Damme, H. Duvillier, K. Pieters, P. Mineur, N. Meuleman, D. Bron, L.L. Lagneaux, B. Stamatopoulous

P1.17 DNA hydroxymethylation in chronic lymphocytic leukemia: TET and IDH mRNA expression, prognostic significance and influence of microenvironment

M. Van Damme, E. Crompot, N. Meuleman, P. Mineur, D. Bron, L. Lagneaux, B. Stamatopoulos

P1.18 Monoclonal B-cell lymphocytosis with a lymphoma phenotype: characterization and prognosis of a patient cohort

S. Vander Meeren, B. Heyrman, W. Renmans, K. Jochmans, M. Bakkus, H. De Raeve, R. Schots, M. De Waele

P1.19 The role of the Anaphase Promoting Complex/ Cyclosome in multiple myeloma cell growth

S. Lub

P1.20 Intravascular lymphoma: A retrospective monocentric observational analysis and review of literature

D. Dierickx, D. Gullentops, G. Verhoef, S. Vanderschueren, T. Tousseyn, O. Gheyssens, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans

P1.22 Characteristics, treatment and prognosis of primary central nervous system lymphoma: a single center retrospective study

D. Dierickx, A. van Mellaert, L. Smets, G. Verhoef, P. Clement, P. Demaerel, T. Tousseyn, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans

P2.01 Functional evaluation of T cells generated from WT1-TCR transduced human hematopoietic stem cells using the OP9-DL1 coculture system

S. Bonte, S. Snauwaert, G. Goetgeluk, M.H.M. Heemskerk, H. Stauss, R. Stripecke, B. Vandekerckhove, T. Kerre

P2.03 Belgian Stop IMatinib trial

P. Mineur, C. Doyen, N. Straetmans, K. Van Eygen, D. Pranger, A. Bosly, M. André, T. Devos, L. Knoops

P2.04 Role of microvesicles derived from leukemic blast in DIC and thrombosis.

D. Gheldof, J-M. Dogné, C. Graux, G. Fabienne, A. Sonet, B. Chatelain, F. Mullier, C. Chatelain

P2.05 Role of extracellular vesicles on multidrug resistance transfer between leukemia cells

C. Bouvy, D. Gheldof, C. Chatelain, F. Mullier, J-M. Dogné

P2.06 Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients

A. Van De Velde, S. Anguille, P. Beutels, S. Dom, I. Cornille, G. Nijs, F. van Tendeloo, E.L. Smits, A. Verlinden, A.P. Gadisseur, W.A. Schroyens, Z.N. Berneman

P2.07 MPN with JAK2 V617F mutation and identical del20q11.2 in three first-degree relatives without identified germline defect

J. Dauw, E. Boone, N. Cardinaels, E. Moureau, A. Nijs, F. Nollet, V. Van Hende, N. Van Roy, K. Van Eygen